Domperidone ( DrugBank: Domperidone )


5 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease6
13Multiple sclerosis/Neuromyelitis optica2
17Multiple system atrophy1
51Scleroderma1
230Alveolar hypoventilation syndrome1

6. Parkinson disease


Clinical trials : 2,307Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

17. Multiple system atrophy


Clinical trials : 119Drugs : 138 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 111 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

51. Scleroderma


Clinical trials : 525Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

230. Alveolar hypoventilation syndrome


Clinical trials : 6Drugs : 7 - (DrugBank : 4) / Drug target genes : 16 - Drug target pathways : 26 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries